Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10980284rdf:typepubmed:Citationlld:pubmed
pubmed-article:10980284lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:10980284lifeskim:mentionsumls-concept:C0081937lld:lifeskim
pubmed-article:10980284lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:10980284lifeskim:mentionsumls-concept:C0184511lld:lifeskim
pubmed-article:10980284lifeskim:mentionsumls-concept:C0178665lld:lifeskim
pubmed-article:10980284lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:10980284lifeskim:mentionsumls-concept:C1256369lld:lifeskim
pubmed-article:10980284pubmed:issue1-2lld:pubmed
pubmed-article:10980284pubmed:dateCreated2000-10-26lld:pubmed
pubmed-article:10980284pubmed:abstractTextWe explored whether inhibition of the enzyme dipeptidyl peptidase IV (DPP IV) increases endogenous levels of glucagon-like peptide-1 (GLP-1) and improves glucose tolerance and insulin secretion in mice. Glucose (150 mg) was administered through a gastric gavage with or without the inhibitor of dipeptidyl peptidase IV, valine-pyrrolidide (100 micromol/kg), in high-fat fed glucose intolerant or control C57BL/6J mice. The increase in plasma GLP-1 after gastric glucose was potentiated by dipeptidyl peptidase IV inhibition (P<0.05). Valine-pyrrolidide also potentiated the plasma insulin response to gastric glucose and improved the glucose tolerance in both groups of mice (P<0.001). In contrast, valine-pyrrolidide did not affect glucose-stimulated insulin secretion from isolated islets. This suggests that valine-pyrrolidide improves insulin secretion and glucose tolerance through indirect action, probably through augmentation of levels of GLP-1 and other incretin hormones. Therefore, inhibition of dipeptidyl peptidase IV activity is feasible to exploit as a treatment for glucose intolerance and type 2 diabetes.lld:pubmed
pubmed-article:10980284pubmed:languageenglld:pubmed
pubmed-article:10980284pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10980284pubmed:citationSubsetIMlld:pubmed
pubmed-article:10980284pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10980284pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10980284pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10980284pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10980284pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10980284pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10980284pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10980284pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10980284pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10980284pubmed:statusMEDLINElld:pubmed
pubmed-article:10980284pubmed:monthSeplld:pubmed
pubmed-article:10980284pubmed:issn0014-2999lld:pubmed
pubmed-article:10980284pubmed:authorpubmed-author:HolstJ JJJlld:pubmed
pubmed-article:10980284pubmed:authorpubmed-author:AhrénBBlld:pubmed
pubmed-article:10980284pubmed:authorpubmed-author:MårtenssonHHlld:pubmed
pubmed-article:10980284pubmed:authorpubmed-author:BalkanBBlld:pubmed
pubmed-article:10980284pubmed:issnTypePrintlld:pubmed
pubmed-article:10980284pubmed:day15lld:pubmed
pubmed-article:10980284pubmed:volume404lld:pubmed
pubmed-article:10980284pubmed:ownerNLMlld:pubmed
pubmed-article:10980284pubmed:authorsCompleteYlld:pubmed
pubmed-article:10980284pubmed:pagination239-45lld:pubmed
pubmed-article:10980284pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:10980284pubmed:meshHeadingpubmed-meshheading:10980284...lld:pubmed
pubmed-article:10980284pubmed:meshHeadingpubmed-meshheading:10980284...lld:pubmed
pubmed-article:10980284pubmed:meshHeadingpubmed-meshheading:10980284...lld:pubmed
pubmed-article:10980284pubmed:meshHeadingpubmed-meshheading:10980284...lld:pubmed
pubmed-article:10980284pubmed:meshHeadingpubmed-meshheading:10980284...lld:pubmed
pubmed-article:10980284pubmed:meshHeadingpubmed-meshheading:10980284...lld:pubmed
pubmed-article:10980284pubmed:meshHeadingpubmed-meshheading:10980284...lld:pubmed
pubmed-article:10980284pubmed:meshHeadingpubmed-meshheading:10980284...lld:pubmed
pubmed-article:10980284pubmed:meshHeadingpubmed-meshheading:10980284...lld:pubmed
pubmed-article:10980284pubmed:meshHeadingpubmed-meshheading:10980284...lld:pubmed
pubmed-article:10980284pubmed:meshHeadingpubmed-meshheading:10980284...lld:pubmed
pubmed-article:10980284pubmed:meshHeadingpubmed-meshheading:10980284...lld:pubmed
pubmed-article:10980284pubmed:meshHeadingpubmed-meshheading:10980284...lld:pubmed
pubmed-article:10980284pubmed:meshHeadingpubmed-meshheading:10980284...lld:pubmed
pubmed-article:10980284pubmed:meshHeadingpubmed-meshheading:10980284...lld:pubmed
pubmed-article:10980284pubmed:year2000lld:pubmed
pubmed-article:10980284pubmed:articleTitleImproved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice.lld:pubmed
pubmed-article:10980284pubmed:affiliationDepartment of Medicine, Malmö University Hospital, Lund University, S-205 02, Malmö, Sweden. bo.ahren@medforsk.mas.lu.selld:pubmed
pubmed-article:10980284pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10980284pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10980284lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10980284lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10980284lld:pubmed